Obermatt

Cipla

NSI:CIPLA · INE059A01026
PharmaceuticalsX-Large

360

53
EV / EBIT28
Price / Owner Earnings35
Owner Earnings Yield47
Dividend Yield63
Price/Sales35
EV / Gross Profit62
Price/Book55
Return on Capital49
Cash Return on Capital42
Return on Equity39
EBIT Margin37
Gross Profitability60
Cash Conversion32
Owner Earnings Margin43
Sales growth37
Profit Growth78
Long-Term EPS Growth31
Reinvestment64
Price momentum39
Debt load87
Refinancing45
Debt Payback100
Liquidity86
Analyst ratings33
Opinion Changes86
Price Target Upside30
Market mood81
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cipla clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryIndia
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeNSEI
Founded1935
Employees18,278
Websitecipla.com
ISININE059A01026
Last UpdateApr 2, 2026
Themes
CardiovascularDiabetesCentral Nervous SystemRespiratoryUrologyInfectious DiseasesOncologyVaccinesNeurologyHealth CareMedicalPharmaceutical

Description

Analysis

Middle-of-the-road

Cipla Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 31.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 12% a year, against analyst forecasts of 6%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is sturdy. The company scores 13/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
94
2023202420252026

All-time high

96

Oct 2025

All-time low

41

Mar 2026

Average rank

77

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
48
50
65
Price/Earnings
45
60
64
65
Price/Book
55
52
60
64
Dividend Yield
63
53
39
39
Value (overall)
62
72
57
67

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cipla with its peers
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Lupin
NSI:LUPIN
67
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Alembic Pharmaceuticals
NSI:APLLTD
51
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Torrent Pharmaceuticals
NSI:TORNTPHARM
18
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Alkem Laboratories
NSI:ALKEM
47
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Granules India
NSI:GRANULES
65
CountryIndia
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →